ASX:NYR

Nyrada (NYR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
65,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Nyrada

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases. Its products in the drug development stage includes PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce the disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.

NYR Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive NYR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nyrada and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-4,980,000.00
Net Margins
-169.82%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.93 million
Book Value
A$0.03 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.54
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. James Bonnar
    Chief Executive Officer
  • Mr. Cameron Jones C.A.
    Chief Financial Officer
  • Mr. Benjamin Evison Ph.D.
    Chief Scientific Officer
  • Mr. Dimitri Burshtein
    Investor Relations Manager
  • Mr. Mark Waring B.Sc.
    P.M.P., Senior Vice President of US Operations
  • Mr. David James Franks BEc (Age 54)
    C.A., F Fin, J.P., Company Secretary

This page (ASX:NYR) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners